Gottfried Himmler
Plus aucun poste en cours
Profil
Dr. Gottfried Himmler is a Head-Clinical & Quality Operations at YGION Biomedical GmbH.
Dr. Himmler was previously employed as a Chief Executive & Scientific Officer by F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH, a Chief Scientific Officer by igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH, a Principal by Codon Devices, Inc., a Managing Director by GenoVision AS, and a Director-Supervisory Board by HELIOVIS AG.
He received his doctorate degree from the University of Natural Resources & Life Sciences.
Postes actifs de Gottfried Himmler
| Sociétés | Poste | Début |
|---|
Anciens postes connus de Gottfried Himmler
| Sociétés | Poste | Fin |
|---|---|---|
GenoVision AS
 GenoVision AS Medical SpecialtiesHealth Technology GenoVision AS develops reagents and solutions for certain nucleic acid diagnostic markets. It has developed products and protocols for the direct isolation of DNA and RNA from a variety of sample sources such as dried blood, leucocytes, serum, buccal cells, cultured cells, biopsy samples, paraffin embedded tissue sections, animal tissue and yeast cells. GenoVision was formed in 1998 and is headquartered in Oslo, Norway | Directeur Général | - |
HELIOVIS AG
 HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | Directeur/Membre du Conseil | - |
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
 F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Directeur Général | - |
Codon Devices, Inc.
 Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
 igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Directeur Technique/Scientifique/R&D | - |
Formation de Gottfried Himmler
| University of Natural Resources & Life Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 5 |
|---|---|
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH
F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH Medical SpecialtiesHealth Technology F-Star Biotechnologische Forschungs- Und Entwicklungsges MBH develops improved therapeutic antibodies and antibody fragments for cancer. It is a biopharmaceutical company dedicated to developing novel bispecific antibody products that significantly improve on the current standard of care for patients with serious diseases such as cancer. The firm's modular antibody technology allows them to rapidly discover and develop bispecific antibodies by introducing additional binding sites to the constant region of an antibody. The company was founded by Florian Ruker, Gordana Wozniak-Knopp, and Gottfried Himmler on June 12, 2006 and is headquartered in Vienna, Austria. | Health Technology |
Codon Devices, Inc.
Codon Devices, Inc. Pharmaceuticals: MajorHealth Technology Codon Devices, Inc. produces pharmaceuticals and biorefineries for the production of industrial chemicals and bio-energy. The firm designs and constructs biological components such as enzymes, biopharmaceuticals, and cell lines for improved function. Its customers include the biotechnology, pharmaceutical, and agriculture sectors. The company was founded by Noubar B. Afeyan, George Church, Drew Endy, Joseph M. Jacobson and Jay Keasling in 2004 and is headquartered in Cambridge, MA. | Health Technology |
GenoVision AS
GenoVision AS Medical SpecialtiesHealth Technology GenoVision AS develops reagents and solutions for certain nucleic acid diagnostic markets. It has developed products and protocols for the direct isolation of DNA and RNA from a variety of sample sources such as dried blood, leucocytes, serum, buccal cells, cultured cells, biopsy samples, paraffin embedded tissue sections, animal tissue and yeast cells. GenoVision was formed in 1998 and is headquartered in Oslo, Norway | Health Technology |
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH
igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH BiotechnologyHealth Technology igeneon Krebs-Immuntherapie Forschungs & Entwicklungs GmbH develops biological products to treat cancer and other diseases. It focuses on cancer immunotherapies designed to prevent or delay the formation of metastases in cancer of epithelial origin, including colorectal, breast and lung cancer. Founded in 1999, the company is headquartered in Vienna, Austria. | Health Technology |
HELIOVIS AG
HELIOVIS AG Electric UtilitiesUtilities HELIOVIS AG develops solar concentrator for large solar power plants. Its product is HELIOtube, a novel type of solar concentrator for large solar power plants which mainly consists of plastic foils. The firm also develops a disruptive-innovative approach that shall find a permanent place in the expansion of solar energy at locations with intensive direct solar radiation. The company was founded by Johannes Hoefler and Felix Tiefenbacher in 2009 and is headquartered in Wiener Neudorf, Austria. | Utilities |
